London, United Kingdom (PressExposure) June 28, 2011 -- GlobalData estimated that the global hyperparathyroidism therapeutics market valued $2 billion in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 17.9% during 2005-2010. It is forecast to grow at a CAGR of 7.6% for the next seven years to reach $3.4 billion by 2017. The major breakthrough in the hyperparathyroidism market was the approval of Sensipar/Mimpara (cinacalcet) by US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) in October, 2004. This growth forecast is primarily based on the increasing prevalence of the disease
GlobalData has found that the hyperparathyroidism therapeutics market has a low level of unmet need, which implies that the market is well-served by the current products and that potential market entry for new drugs is limited. Hyperparathyroidism therapies are primarily targeted at increasing the overall survival of patients with secondary hyperparathyroidism in chronic kidney disease. However, a new drug that increases overall survival through superior efficacy and tolerability compared to currently marketed products will find a place in the market. In summary, the hyperparathyroidism market is expected to be a relatively less open market for new entrants until 2017, with few opportunities to capture significant market value.
GlobalData's research indicates that the pipeline for hyperparathyroidism is weak, with only five molecules in various stages of clinical development. There is only one first-in-class molecules across all of the phases of development. CTA018 has been evaluated as the promising molecule in the hyperparathyroidism pipeline due to its novel mechanism of action. CTA018 has a dual mechanism of action combining vitamin-D agonist actions with the inhibition of the CYP24 enzyme for enhanced efficacy and tolerability.
For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Hyperparathyroidism-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
Currently, two molecules, or 40%, of the total hyperparathyroidism pipeline is in Phase II of clinical development, and three molecules, representing 60%, of the pipeline are in Phase I of clinical development, suggesting a weak pipeline.
GlobalData, the industry analysis specialist, has released its new report, "Hyperparathyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Hyperparathyroidism Therapeutics market. The report identifies the key trends shaping and driving the global Hyperparathyroidism Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hyperparathyroidism Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com/reportstore
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782